Literature DB >> 1287416

Monoclonal antibodies against human fibroblast collagenase and the design of an enzyme-linked immunosorbent assay to measure total collagenase.

I M Clark1, L K Powell, J K Wright, T E Cawston, B L Hazleman.   

Abstract

Monoclonal antibodies have been raised against purified human fibroblast collagenase and characterised. One of these antibodies has been used in combination with a polyclonal anticollagenase antibody in a double antibody sandwich ELISA to measure collagenase. The assay range was 2-50 ng/ml collagenase. The assay measures total collagenase, i.e. pro- and active enzyme as well as collagenase in complex with TIMP. The level of collagenase has been measured in sera samples from patients with rheumatoid arthritis and compared with age- and sex-matched controls. The levels measured were: rheumatoid arthritis, 69 +/- 29 ng/ml; normal, 49 +/- 14 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287416     DOI: 10.1016/s0934-8832(11)80092-2

Source DB:  PubMed          Journal:  Matrix        ISSN: 0934-8832


  10 in total

1.  Measurement of activity of collagenolytic MMP and inhibitors of MMPs using radiolabeled collagen substrate.

Authors:  Tim E Cawston
Journal:  Nat Protoc       Date:  2009-02-12       Impact factor: 13.491

2.  Esculetin inhibits cartilage resorption induced by interleukin 1alpha in combination with oncostatin M.

Authors:  S Elliott; A D Rowan; S Carrère; P Koshy; J B Catterall; T E Cawston
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

3.  Collagenolytic matrix metalloproteinases antagonize proteinase-activated receptor-2 activation, providing insights into extracellular matrix turnover.

Authors:  Adrian M D Falconer; Chun Ming Chan; Joseph Gray; Izuru Nagashima; Robert A Holland; Hiroki Shimizu; Andrew R Pickford; Andrew D Rowan; David J Wilkinson
Journal:  J Biol Chem       Date:  2019-05-19       Impact factor: 5.157

4.  Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.

Authors:  S A Young-Min; C Beeton; R Laughton; T Plumpton; S Bartram; G Murphy; C Black; T E Cawston
Journal:  Ann Rheum Dis       Date:  2001-09       Impact factor: 19.103

5.  Protein kinase C isoforms zeta and iota mediate collagenase expression and cartilage destruction via STAT3- and ERK-dependent c-fos induction.

Authors:  Gary J Litherland; Martina S Elias; Wang Hui; Christopher D Macdonald; Jonathon B Catterall; Matt J Barter; Matthew J Farren; Matthew Jefferson; Andrew D Rowan
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

6.  Human nasal cartilage responds to oncostatin M in combination with interleukin 1 or tumour necrosis factor alpha by the release of collagen fragments via collagenases.

Authors:  T G Morgan; A D Rowan; S C Dickinson; D Jones; A P Hollander; D Deehan; T E Cawston
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

7.  Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage.

Authors:  R C Billinghurst; L Dahlberg; M Ionescu; A Reiner; R Bourne; C Rorabeck; P Mitchell; J Hambor; O Diekmann; H Tschesche; J Chen; H Van Wart; A R Poole
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

8.  Human shoulder tendon biopsy samples in organ culture produce procollagenase and tissue inhibitor of metalloproteinases.

Authors:  S Dalton; T E Cawston; G P Riley; I J Bayley; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1995-07       Impact factor: 19.103

9.  Monocyte matrix metalloproteinase production in Type 2 diabetes and controls--a cross sectional study.

Authors:  Mark D Baugh; Jelena Gavrilovic; Isabel R Davies; David A Hughes; Mike J Sampson
Journal:  Cardiovasc Diabetol       Date:  2003-03-10       Impact factor: 9.951

10.  Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases.

Authors:  P Harvey; I M Clark; M C Jaurand; R M Warn; D R Edwards
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.